These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2093542)

  • 21. Treatment of uraemic anaemia with recombinant human erythropoietin.
    Ponticelli C; Casati S; Campise M
    Adv Exp Med Biol; 1989; 260():53-9. PubMed ID: 2696371
    [No Abstract]   [Full Text] [Related]  

  • 22. [Erythropoietin: its biological properties and clinical use].
    Ermolenko VM; Nikolaev AIu
    Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979
    [No Abstract]   [Full Text] [Related]  

  • 23. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial hypertension in uraemic patients treated with erythropoietin.
    Kokot F; Wiecek A
    Nephron; 1995; 71(2):127-32. PubMed ID: 8569941
    [No Abstract]   [Full Text] [Related]  

  • 25. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
    Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M; Miyazono K; Urabe A; Takaku F
    Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human erythropoietin corrects anemia of blood loss: a study in the dog.
    Koumegawa J; Kawahara J; Kubo K; Amano K; Wakimoto N; Takahashi K; Juji T; Takaku F
    Int J Cell Cloning; 1990 Mar; 8(2):97-106. PubMed ID: 2313141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correction of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysis.
    Li PK; Leung CB; Lui SF; Leung JC; Shek AC; Lai KN
    Int J Artif Organs; 1993 Jul; 16(7):510-4. PubMed ID: 8370605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis].
    Ermolenko VM; Khvoĭnitskiĭ VA; Suprun EK; Tsukerman LI; Pokrovskiĭ IuA
    Ter Arkh; 1992; 64(7):86-8. PubMed ID: 1440377
    [No Abstract]   [Full Text] [Related]  

  • 30. Guidelines for the use of recombinant human erythropoietin.
    Barosi G; Cazzola M; De Vincentiis A; Grossi A; Tura S
    Haematologica; 1994; 79(6):526-33. PubMed ID: 7896210
    [No Abstract]   [Full Text] [Related]  

  • 31. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 32. Recombinant human erythropoietin activates a broad spectrum of progenitor cells.
    Stockenhuber F; Kurz RW; Geissler K; Jahn C; Hinterberger W; Balcke P; Lechner K
    Kidney Int; 1990 Jan; 37(1):150-6. PubMed ID: 2299802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and side effects of erythropoietin used in the treatment of anemia of uremic rats.
    Gretz N; Lasserre J; Kraft K; Waldherr R; Weidler B; Meisinger E; Strauch M
    Contrib Nephrol; 1988; 60():236-44. PubMed ID: 3345672
    [No Abstract]   [Full Text] [Related]  

  • 34. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of mild anemia.
    Waltzman RJ
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-38-41. PubMed ID: 23570098
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of recombinant human erythropoietin on anemia and dialysis: efficiency in patients undergoing CAPD.
    Schollmeyer P; Lubrich-Birkner I; Steinhauer HB
    Contrib Nephrol; 1990; 87():95-104. PubMed ID: 2093545
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of withdrawing erythropoietin.
    Taylor JE; Henderson IS; Mactier RA; Stewart WK
    BMJ; 1991 Feb; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract]   [Full Text] [Related]  

  • 38. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
    Am J Kidney Dis; 1989 Sep; 14(3):163-9. PubMed ID: 2672796
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 40. Erythropoietin and the myelodysplastic syndrome.
    Jacobs A; Culligan D; Bowen D
    Contrib Nephrol; 1991; 88():266-70. PubMed ID: 2040188
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.